Flash sensor-based glucose monitoring (FSGM) provides people with diabetes with an exhaustive overview about their glycemic control. However, the plethora of data can also be challenging and overwhelming. We developed a treatment and education program for FSGM-use (named FLASH) and evaluated its efficacy in a randomized controlled trial. We included people with diabetes on an intensified insulin therapy who either already used FSGM before the study (FSGM-experienced) or who newly used FSGM with the beginning of the study (FSGM-naïve). All participants were either randomized to receiving the FLASH education or to a treatment-as-usual control group. We report on results of ANCOVA with baseline-adjusted HbA1c and diabetes distress values at follow-up, respectively. A total of 199 participants were analyzed. FSGM-experienced participants were using FSGM for a mean duration of 7.9 ± 9.5 months before study start. At the six-month follow-up, FLASh led to a significant reduction in HbA1c (8.06% vs. 8.22%; p=0.033) and diabetes distress (1.16 vs. 1.00; p = 0.027). However, independent from the group allocation, FSGM-experienced participants (n=121) had significantly higher distress levels at follow-up than FSGM-naïve (n=78) participants (1.16 vs. 1.01; p = 0.032). FSGM-experienced users that never received education had a significantly higher distress level (1.26) than FSGM-experienced users that received education (1.06; p = 0.045), FSGM-naïve users with education (0.95; p = 0.003) and without education (1.06; p = 0.021). The FLASH education led to a reduction in distress. Previous FSGM-use without education was associated with the highest distress, whereas FSGM-naïve participants who received the FLASH education had the lowest distress levels. Thus, results indicate that FSGM-use accompanied with FLASH education is more beneficial than FSGM-use alone. In addition, FSGM-specific education should be employed better sooner than later.

Disclosure

B. Kulzer: Advisory Panel; Self; Ascensia Diabetes Care, Berlin-Chemie AG, Medtronic, Novo Nordisk Inc., Roche Diabetes Care. Research Support; Self; Abbott, Berlin-Chemie AG, Roche Diabetes Care. Speaker's Bureau; Self; Abbott, Ascensia Diabetes Care, Berlin-Chemie AG, Eli Lilly and Company, Novo Nordisk Inc., Roche Diabetes Care. L. Priesterroth: None. N. Hermanns: Advisory Panel; Self; Abbott. Board Member; Self; Eli Lilly and Company. Research Support; Self; Abbott, Berlin-Chemie AG, Dexcom, Inc., Roche Diabetes Care. Speaker's Bureau; Self; Berlin-Chemie AG, Dexcom, Inc., Novo Nordisk A/S. T. Haak: Advisory Panel; Self; Abbott, AstraZeneca, Merck Sharp & Dohme Corp., Roche Diabetes Care. Research Support; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH. Speaker's Bureau; Self; Abbott, AstraZeneca, Berlin-Chemie AG, Eli Lilly and Company, Novo Nordisk Inc. D. Ehrmann: Advisory Panel; Self; Medtronic. Speaker's Bureau; Self; Abbott, Berlin-Chemie AG, Dexcom, Inc.

Funding

Abbott Diabetes Care Germany

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.